Piribedil

• UNSPSC Description:

  Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC50: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers[1][2][3][4].

• Target Antigen:

  Adrenergic Receptor; Dopamine Receptor; Histone Methyltransferase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;GPCR/G Protein;Neuronal Signaling

• Field of Research:

  Cancer; Endocrinology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Piribedil.html

• Purity:

  99.92

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles:

  C1(N2CCN(CC3=CC=C(OCO4)C4=C3)CC2)=NC=CC=N1

• Molecular Weight:

  298.34

• References & Citations:

  [1]Sweet RD, et al. Piribedil, a dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther. 1974 Dec;16(6):1077-82. |[2]Gerlach M, et al. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. J Neural Transm (Vienna). 2013 Jan;120(1):31-6. |[3]Smith LA, Tet al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17(5):887-901.|[4]Xiong Zhang, et al. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Cancer Lett. 2018 Sep 1;431:150-160.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  3605-01-4